4.3 Article

Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 16, Issue 9, Pages 1148-1151

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458510375440

Keywords

brain atrophy; cognitive intervention; executive functioning; multiple sclerosis

Funding

  1. Sanofi-Aventis Inc.
  2. Bayer HealthCare Inc.
  3. Merck-Serono Inc.
  4. Villigst foundation (study foundation of the protestant church)

Ask authors/readers for more resources

We evaluated a rehabilitation programme for executive deficits in multiple sclerosis patients by comparing outcome scores of a cognitive intervention group (CIG; n = 11) with those of a placebo group (n = 14) and an untreated group (n = 15). Executive functioning and verbal learning improved significantly more in the CIG. The treatment effect on verbal learning was still present at 1-year follow-up. Baseline brain atrophy, quantified by the brain parenchymal fraction, was associated with treatment effects for one aspect of executive functioning. Consequently, cognitive intervention may be beneficial and baseline brain atrophy has some predictive value in determining treatment outcome for executive functioning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available